Please assess the completion status of the following clinical trial:

Trial Title: Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age ≥ 18 years~* Normal ophthalmic findings except dry eye disease~* Ametropy ≤ 6 diopters~* Chronic dry eye defined as longer than six months since diagnosis~* OSDI ≥ 22~* Conjunctival Hyperemia ≥ Grade 3 (Efron Scale)~* Current use of topical lubricants since at least 3 months~Exclusion criteria:~* Best far corrected visual acuity \< 1/10~* Severe Dry Eye associated with:~* Eyelid malposition~* Sjogren Syndrome~* Steven Johnson Syndrome~* Corneal dystrophy~* Ocular neoplasia~* Filamentous keratitis~* Corneal neovascularisation~* Orbital radiotherapy~* History of any of the following within last 3 months:~* Systemic treatment of dry eye~* Systemic treatment of MGD~* Isotretinoide,~* Cyclosporine,~* Tacrolimus, Siromilus, Pimecrolimus~* Punctual plugs~* Anti-glaucoma treatment~* History of any of the following within previous six months:~* ocular trauma~* ocular infection, ocular allergy~* History of any of the following within last 12 months:~* inflammatory corneal ulcer~* Herpetic eye infection or uveitis~* Ocular surgery~* History of IOP increase caused by systemic or topical treatment with corticosteroids~* IOP \> 22mmHg~* Glaucoma in the medical history~* Known hypersensitivity to any of the components of the IMP under investigation or other study medication~* Allergic rhinitis; active or susceptible to reactivation during the study~* Pregnant or breast-feeding woman.~* Woman of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (oral contraceptives, intrauterine device, contraceptive implant or condoms)~* Inability of patient to understand the investigation procedures and thus inability to give valid, informed consent.~* Non-compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance)~* Participation in another clinical study or clinical investigation at the same time as the present investigation~* Participation to the present clinical investigation during the exclusion period of another clinical study~* Patient already included once in this clinical investigation~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intense (Type: EXPERIMENTAL): Patients have been randomized to receive Softacort eye drops for 12 days 4 times daily followed by 2 days twice daily treatment resulting in a total time of 14 days
- standard (Type: EXPERIMENTAL): Patients have been randomized to receive Softacort eye drops for 8 days 3 times daily followed by 3 days twice daily treatment resulting in a treatment time of 11 days total

Based on this trial design, predict the completion outcome and termination type (if applicable).